Research and Development | CHADIS

CHADIS Research and Development

Funding

CHADIS has been developed with the assistance of grant funding from a number of agencies and sponsors.  Drs. Sturner and Howard have acted as principal investigators with the assistance of the CHADIS research staff and many other professional collaborators.

These grants include support from the following granting agencies:  The Abell Foundation, the Wilson Foundation, the Commonwealth Fund, The Erickson Foundation, The Cisco Foundation, The State of Maryland, and the Maternal Child Health Bureau and the National Institutes of Health (NIH).

In addition, thirteen SBIR (Small Business Innovative Research) awards were given for purposes of CHADIS research and development through Total Child Health, including seven from the National Institutes of Mental Health (NIMH) and two from the National Institute of Child Health and Development (NICHD), two from the National Heart Lung and Blood Institute (NHLBI), one from the National Institute on Drug Abuse (NIDA), and one from the Center for Disease Control (CDC).

In addition, we have completed subcontracts aimed at developing modules for CHADIS as co-investigators with support from the Doris Duke Charitable Foundation and Substance Abuse and Mental Health Agency (SAMSHA).

Financial Conflict of Interest Policy (FCOI)

Current Grant Projects:

September 2022

Phase II has been funded. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded CHADIS a grant for the Validation of the Online Toddler Autism and Development Adaptive Screener (TADAS) at 18 months.

September 2021

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded CHADIS a grant for the Validation of the Online Toddler Autism and Development Adaptive Screener (TADAS) at 18 months.

The American Academy of Pediatrics has mandated identification of autism beginning at the routine 18-month visit, based on evidence that early intervention for children with autism improves outcomes, but there are concerns about the accuracy of currently available screening tools at that age.

This project builds on data from a previous grant showing that using machine learning algorithms individualizing presentation of items to screen for autism and developmental delay (called TADAS) dramatically improved accuracy of screening with lesser parent burden and benefits to office workflow.

The proposed study is required to bring this promising tool to clinical use by programming it into our online clinical process support system (CHADIS) and then completing validation in a new community sample of toddlers weighted to be representative of the U.S. population.

Publications and Presentations:

June 2022

O’Connell M, Plumb J, Howard B, Sturner R, Shrier LA, Harris SK. Trends in substance use screening results before and during the COVID-19 pandemic among youth in pediatric primary care. Poster presented at: Dr. M. Judah Folkman Research Day; Boston Children's Hospital; Jun 1, 2022; Virtual (Boston, MA).

May 2022

Sturner R, Bergmann P, Howard B, Bet K, Stewart-Artz L, Attar S. Do Autism-Specific and General Developmental Screens Have Complementary Clinical Value? J Autism Dev Disord. 2023 Aug;53(8):3065-3076. doi: 10.1007/s10803-022-05541-y. Epub 2022 May 17. PMID: 35579791; PMCID: PMC10214166.

April 2022

O’Connell M, Plumb J, Howard B, Sturner R, Shrier LA, Harris SK. Trends in substance use screening results before and during the COVID-19 pandemic among youth in pediatric primary care. Poster presented at: Pediatric Academic Societies (PAS) Meeting; Apr 21-25, 2022; Denver, CO.

January 2022

Holcomb, Juliana M.; Dutta, Anamika; Bergmann, Paul; Riobueno-Naylor, Alexa; Haile, Haregnesh; Benheim, Talia S.; Sturner, Raymond; Howard, Barbara; Jellinek, Michael; Murphy, J. Michael, Suicidal Ideation in Adolescents: Understanding Results from Screening with the PHQ-9M and the PSC-17P.

Sturner, R., Howard, B., Bergmann, P. et al. Autism screening at 18 months of age: a comparison of the Q-CHAT-10 and M-CHAT screeners. Molecular Autism 13, 2 (2022). DOI: 10.1186/s13229-021-00480-4

November 2021

Delgado-Martinez R, Barry MF, Porras-Javier L, Thompson LR, Howard BJ, Sturner R, Halterman JS, Szilagyi PG, Okelo SO, Dudovitz RN. What Parents Want Doctors to Know: Responses to an Open-Ended Item on an Asthma Questionnaire. Acad Pediatr. 2021 Nov 17:S1876-2859(21)00543-X. doi: 10.1016/j.acap.2021.11.007.

October 2021

Raymond  Sturner, Barbara Howard, MD, Beth Wildman,  Nathan Suberi Dawn Lewis, PA, MPH, Kerry Bet, MPH, Yidan Cao. Parent report of Forward-Actionable Positive Childhood Experiences (FA-PCE) improves the clinical utility of the standard ACE presented at the annual meeting of the Society for Developmental and Behavioral Pediatrics, virtual, October 2021.

... (Additional citations continue in a similar format)

Announcements:

December 2016

CHADIS receives NICHD award aimed at reduction of child maltreatment and addressing family stress.  A unique family stress "patient specific template" has been created for this purposes and is being further refined through clinical simulations with primary care pediatricians and feedback from a diverse group of parents.  This module will be studied further in a large-scale cluster randomized trial.  Click to view Family Stress Grant Summary.

CHADIS American Board of Pediatrics (ABP) Portfolio Sponsor status renewed for the Maintenance of Certification (MOC-4) program. CHADIS is unique in matching patient-generated data with prompted clinician decision making so chart reviews are not needed.  Portfolio Sponsors are programs recognized as having demonstrated success in creating approved quality improvement processes for formal re-certification of specialty status and are able to create their own programs on behalf of the ABP.  CHADIS offers MOC-4 for the following areas: Autism Screening; Developmental Screening; Asthma; ADHD; and Family Stress.